Pegdinetanib

From WikiMD.org
Jump to navigation Jump to search

Pegdinetanib

Pegdinetanib (pronunciation: peg-din-e-tan-ib) is a novel biopharmaceutical drug currently under investigation for its potential use in the treatment of various types of cancer.

Etymology

The name "Pegdinetanib" is derived from the drug's chemical structure and its intended therapeutic use. "Peg" refers to Pegylation, a process that involves the attachment of polyethylene glycol (PEG) to a molecule, in this case, a drug. "Dinetanib" is a combination of syllables often used in the nomenclature of tyrosine kinase inhibitors, a class of drugs that Pegdinetanib belongs to.

Mechanism of Action

Pegdinetanib is a tyrosine kinase inhibitor that works by blocking the action of certain proteins that signal cancer cells to grow and divide. By inhibiting these proteins, the drug can slow down or stop the growth of cancer cells.

Related Terms

  • Biopharmaceutical: A type of drug produced using biotechnology.
  • Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
  • Pegylation: A process that involves the attachment of polyethylene glycol (PEG) to a molecule.
  • Tyrosine kinase inhibitors: A class of drugs that block the action of tyrosine kinases, proteins that can stimulate cancer growth.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski